Methylation-driven gene DLL3 is a potential prognostic biomarker in ocular melanoma correlating with metastasis

Ludi Yang1,2†, Gaoming Wang3†, Hanhan Shi1,2†, Shichong Jia4, Jing Ruan1,2*, Ran Cui3* and Shengfang Ge1,2*

1Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, 2Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China, 3Department of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, 4Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Visual Science, Nankai University Affiliated Eye Hospital, Tianjin Eye Institute, Tianjin, China

Background: Ocular melanoma is an aggressive malignancy with a high rate of metastasis and poor prognosis. Increasing evidence indicated that DNA methylation plays an important role in the occurrence and development of ocular melanoma. Hence, exploring new diagnostic and prognostic biomarkers at the genetic level may be beneficial to the prognosis of patients with ocular melanoma.

Methods: We collected DNA methylation and gene expression profiles of human UM (uveal melanoma) and CM (conjunctival melanoma) samples from various datasets. We conducted differential methylation and expression analyses to screen the potential biomarkers. Correlation analysis was performed to investigate the relationships between the expression level of DLL3 (delta-like protein 3) and the methylation level of its corresponding CpGs. We explored the prognostic and diagnostic value of DLL3 in UM and CM. Functional annotation and GSEA (gene set enrichment analysis) were applied to get insight into the possible biological roles of DLL3. External datasets, biospecimens, and cell lines further validated the aberrant expression and prognostic role of DLL3 in ocular melanoma.

Results: We found that DLL3 was a methylation-driven gene correlating with UM metastasis. The CpGs of DLL3 are mainly located in the gene body and their methylation level positively correlated to DLL3 expression. Multivariate Cox regression analysis revealed that DLL3 was an independent protective factor for UM patients. High DLL3 expression significantly prolonged the overall survival and disease-free survival of UM patients. DLL3 also showed a promising power to distinguish CM from normal tissues. Functional annotation exhibited that DLL3 may suppress UM progression through modulating immune activities and down-regulating various signaling pathways. External datasets, biospecimens, and cell lines further validated the aberrant expression and prognostic role of DLL3 in ocular melanoma.
Introduction

Ocular melanoma is the 2nd common melanoma in adults and may originate intraocularly from the uvea or extraocular from the conjunctiva. Ocular melanoma is an aggressive malignancy with a high rate of metastasis and poor prognosis (1–4). Oncogenic mutations in G-protein subunits α, q (GNAQ) and 11 (GNA11) have been described in 80% of uveal melanomas (UM) (5), which could activate YAP/TAZ pathway and lead to abnormal cellular proliferation. BAP1 deletion and chromosomal anomalies have also been identified in UM (6, 7). Compared with uveal melanoma, conjunctival melanoma (CM) presents distinct gene expression patterns (8). Several oncogenic factors have been found in CM, such as BRAF, NRAS, and TERT mutations. These mutations are distinct from the mutations found in UM. Currently, most therapies on these genetic deficiencies have modest efficacy in both UM and CM. Consequently, exploring the molecular mechanism of ocular melanoma and determining the prognostic factors at the genetic level for early diagnosis is particularly important.

Loss of epigenetic homeostasis plays an important role in tumorigenesis by disrupting the normal pattern of gene expression (9). DNA methylation is a common epigenetic modification that regulates gene expression (10). Hypermethylation of the promoter CpG island is a major factor in tumorigenesis by inhibiting tumor suppressor genes (11). Evidence has also been presented that gene body DNA methylation can promote gene expression (12). In recent years, more and more studies have shown that DNA methylation plays an important role in the occurrence and development of ocular melanoma (13, 14). For example, p16INK4a, an inhibitor of cyclin-dependent kinases 4 and 6, plays an important role in the pRB tumor-suppressor pathways (15). Inactivation of p16INK4a gene through promoter hypermethylation has been frequently observed in various cancers. In UM, the promoters of p16INK4a were hypermethylated accompanied by a decrease in p16INK4a expression (16). In terms of conjunctival melanoma, p16INK4a seems to be a good marker to identify melanoma from nevi and PAMs (17). RASSF1A, a tumor suppressor gene, has been found to be downregulated in many cancers (18). Promoter methylation of RASSF1A and decreased RASSF1A expression were found in both UM and CM (19).

RASSF1 is a tumor suppressor gene that controls tumor growth by inhibiting the RAS pathway. RASEF gene promoter hypermethylation was detected in UM samples without RASEF expression (20) (21). Many other genes are implicated in the loss of epigenetic homeostasis in ocular melanoma, such as TIMP3, MGMT, hTERT, and RARB in UM and APC, CDKN2A, and WIFI in CM (19).

Methylations of DNA have gradually demonstrated their value in the diagnosis of ocular melanoma and have become a potential new diagnostic tumor marker. In this study, we analyzed methylation and transcriptome profiles to find prognostic indicators related to abnormal methylation in UM. Integrated analyses of multiple ocular melanoma datasets revealed that DLL3 was a dysregulated methylation-driven gene in UM metastasis and could serve as a biomarker to predict the prognosis of patients with UM. Results from biospecimens and cell lines further confirmed the prognostic value and expression pattern of DLL3 in ocular melanoma. The findings may be beneficial to therapeutic customization and medical decision-making.

Methods

Data collection and preparation

The methylation (Illumina HumanMethylation450 BeadChip) and transcriptome (RNA-Seq) profiles of 80 UM tissues were obtained from The Cancer Genome Atlas (TCGA) database (TCGA-UVM, https://portal.gdc.cancer.gov/). The corresponding clinicopathological information of UM patients from TCGA was obtained from the cBioPortal website (22) (https://www.cbioportal.org/). Considering that there were no normal tissues in TCGA-UVM, we downloaded another dataset (GSE57362 (23)) containing only methylation (Illumina HumanMethylation450 BeadChip) profiles of 10 uvea tissues and 15 UM samples from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). Other 57 UM cases from GSE44295 (Zhang’s cohort, platform: Illumina HumanRef-8 v3.0 expression beadchip) were employed for validation. GSE143952 (Mikkelsen’s cohort, platform: NanoString Custom
Bioinformatics analysis

A total of 485,512 DNA methylation probes were obtained and the methylation data were analyzed with the R package “ChAMP” (25). Principal component analysis (PCA) was conducted to detect the differences between samples based on the methylation profiles. After removing the abnormal samples, differential methylation analysis was performed to identify the dysregulated CpG sites between UM samples and normal uvea tissues with the thresholds of |log2FoldChange| > 0.5 and adjust p-values (padj) < 1×10^{-5}. The prognostic CpG sites were screened through univariate Cox regression analysis on the basis of UM patients from TCGA with the cut-off criteria of p-value < 0.05.

Differentially expressed genes (DEGs) between non-metastatic and metastatic UM samples were calculated based on the count matrix with the R package “DESeq2” (26). Those genes with |log2FoldChange| > 0.5 and padj < 0.05 were selected as metastasis-related genes. The possible biological function of DLL3 was annotated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses through the R package “clusterProfiler” (27). Gene set enrichment analysis (GSEA) was conducted to explore the potential regulatory mechanisms of DLL3 with the annotated gene sets in “h.all.v7.4.symbols.gmt” as reference (28). The results of bioinformatics analyses were visualized utilizing the R packages “ggplot2”, “pheatmap”, “survminer”, and “VennDiagram”.

Patient samples

60 human ocular melanoma tissues and 18 human normal melanocyte tissues were collected from patients in Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine from 2007 to 2017. Histological characteristics of all samples were assessed by pathologists according to standard criteria, and clinicopathological characteristics of patients with ocular melanoma are listed in Table S1.

Cell lines

The PIG1 human normal melanocyte cell line was kindly provided by the Department of Ophthalmology, Peking University Third Hospital. Human retinal pigment epithelium cell line ARPE-19 was purchased from ATCC. Human UM cell lines OMM2.3, OMM1, MEL290 as well as the human conjunctival melanoma cell lines CRMM1, CRMM2, and CM2005.1 were kindly given by Prof. Martine J. Jager (Department of Ophthalmology, Leiden University Medical Center, The Netherlands). UM cell line 92.1 was kindly provided by Professor John F Marshall (Tumor Biology Laboratory, John Vane Science Centre, London, UK). All cell lines used in this study were authenticated with STR profiling.

Cell culture

PIG1, ARPE-19, MEL290, OMM2.3, OMM1, 92.1 and CM2005.1 cells were cultured in RPMI 1640 medium (GIBCO). CRMM1 and CRMM2 cells were cultured in Ham’s F-12 K (Kaighn’s) Medium (GIBCO). All mediums were supplemented with 10% heat-inactivated fetal bovine serum (FBS; GIBCO), 100 U/ml penicillin, and 100 mg/ml streptomycin and all cells were cultured at 37°C in a humidified 5% CO2 atmosphere.

Immunofluorescence

Cells which are adhering to a glass slide were fixed with 4% formaldehyde (Fisher) for 15 min, then blocked with 5% normal goat serum (Vector) with 0.1% Triton X-100 in PBS for 60 min at room temperature. Immunostaining was performed by using the appropriate primary and secondary antibodies. Nuclei were counterstained with DAPI. IF staining was performed with the appropriate secondary antibody (Invitrogen, 1:1000 dilution). Images were taken with a ZEISS Axio Scope A1 Upright Microscope.

Isolation of RNA and Quantitative Real-Time RT-PCR

Total RNA was extracted from samples using the EZpress RNA Purification Kit (R0004), and cDNA was generated using the PrimeScript RT Reagent Kit (Takara). Quantitative real-time PCR using Powerup SYBR Green PCR Master Mix (Life Technologies) was performed using a real-time PCR system (Applied Biosystems), with the following procedures: 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. The changes in the mRNA levels were quantified using GAPDH mRNA as the control. The primers used in this study were as follows: DLL3-F, 5′-GGGCAGCTGTAGTGAACCTT-3′; DLL3-R, 5′-CTTCACCGGCAACACAAG-3′; GAPDH-F, 5′-GAGCTGAACGGGAAGCTACATG-3′; GAPDH-R, 5′-TGGTGCTCAGTGAGCCAGGA-3′.
Statistical analysis

The analyses were performed using GraphPad Prism 9 and R software (version 4.1.0). We applied Wilcoxon rank-sum test to analyze the difference in gene expression between two groups. The Kaplan–Meier method was applied to produce the survival curve and the difference between groups was compared with the log-rank test. Pearson correlation test was conducted to evaluate the relationship between two variables. Univariate and multivariate Cox regression analyses were employed to assess the prognostic value of factors. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) values were introduced to evaluate the predictive performance. Statistical significance was set at p-value <0.05.

Results

DLL3 was a dysregulated methylation-driven gene in UM metastasis

Since aberrant DNA methylation may contribute to tumor progression (29), we first analyzed the methylation data of 15 UM samples and 10 normal uvea tissues from GSE57362. The quality control step was first conducted to minimize the statistical error caused by abnormal samples. Although the UM and uvea tissues exhibited obvious dissimilarity (Figure S1A), there were still three samples not well clustered (Figure S1B). After removing those outlier samples, a total of 13 UM samples and 9 uvea tissues that showed distinct differences were left for the following analyses (Figure S1C). We subsequently performed differential methylation analysis to identify the dysregulated CpGs. Compared to normal uvea tissues, a total of 5,303 upregulated and 1,471 downregulated CpGs were screened in the UM samples (Figure 1A). To evaluate the prognostic value of CpGs, we utilized univariate Cox regression analysis based on the clinical and methylation data obtained from TCGA. Of 394,475 candidate CpGs, 65,148 CpGs were found to be significantly correlated with the OS (overall survival) of UM patients.

As metastasis is common in UM and seriously threatens the survival of UM patients, we tried to figure out the key genes correlating with metastasis. DEGs between non-metastatic and metastatic UM samples were calculated, and there were 6 upregulated and 63 downregulated genes screened in the metastatic samples compared to the non-metastatic ones (Figure 1B and Table S2). The correlation between the DEGs expression level and their DNA methylation level was also
investigated in UM (Table S3). Taking an intersection for the survival-related CpGs and dysregulated CpGs, 1,262 overlappings were obtained and considered as survival-related dysregulated CpGs (Figure 1C). After annotation of these survival-related dysregulated CpGs, 629 methylation-driven genes were identified. Finally, DLL3 was screened as the only methylation-driven gene of interest associated with UM metastasis (Figure 1D and Table S4).

DLL3 served as a biomarker correlating with the prognosis of patients with UM

DNA methylation regulates gene expression and the function varies with the location of methylation sites (30). Existing evidence indicated that DNA methylation in promoters suppresses gene expression, while gene body methylation may stimulate expression (12). cg06664357 was one of the survival-related dysregulated CpGs and located in the gene body of DLL3. In this study, we analyzed the relationship between cg06664357 and DLL3, founding that DLL3 expression increased with the methylation level of cg06664357 (R = 0.56, p < 0.001, Figure 2A). To determine whether it was an exceptional case, we also analyzed other CpGs located in the DLL3 gene. As shown in Figure S2, DLL3 expression was positively correlated with the methylation levels of most CpGs. Since most CpGs of DLL3 belong to the gene body, it’s not surprising that the methylation of DLL3 promoted its expression. Based on the relationship between DNA methylation and gene expression of DLL3, we speculated that DLL3 was upregulated in UM tissues because all the CpGs of DLL3 exhibited higher methylation levels compared to normal uvea.

To investigate the prognostic value of DLL3 in patients with UM, we employed multivariate Cox regression to analyze the connections between DLL3 expression together with clinicopathological characteristics and OS. Depicted as a forest plot in Figure 2B, our results revealed that DLL3 expression was an independent protective factor for the OS of patients with UM (p = 0.031). We subsequently explored the association between DLL3 expression and various clinical features of UM patients. Increased expression level of DLL3 was negatively correlated with the pathological stage (Figure 3A). Besides, UM patients with higher expression level of DLL3 seemed to exhibit better clinical outcomes (Figure 3B). The mean level of DLL3 expression of UM samples in the disease-free group was higher than that in the progressed group although there was no statistical difference (Figure 3C). To further get insight into the prognostic significance of DLL3, we assigned the UM patients into high and low DLL3 expression groups according to the optimal cutoff value. Kaplan-Meier curves demonstrated that UM patients in the high DLL3 expression group showed a longer survival time (p = 0.0042, Figure 3D). In addition, high DLL3 expression also prolonged the disease-free survival (Figure 3E). Taken together, DLL3 may serve as a prognostic biomarker for patients with UM.

Exploration of the biological function of DLL3 in UM

To get an insight into the potential regulatory mechanisms underlying DLL3, we divided UM patients into high and low DLL3 expression groups according to the median level. Compared to the low DLL3 expression group, a total of 1,978 DEGs consisting of 1,111 upregulated and 867 downregulated
genes were screened (Table S2). GO enrichment analysis revealed that the DLL3-related DEGs mainly participated in immunoregulation and responses including "T cell activation", "regulation of leukocyte cell-cell adhesion", "immune receptor activity", "peptide antigen binding", and others (Figure 4A and Table S5). Notably, at the cellular component (CC) levels, the enriched items such as "external side of plasma membrane" and "plasma membrane signaling receptor complex" indicated that DLL3 played an important role on the cell membrane which agrees with that DLL3 is a cell surface Notch ligand (31). KEGG annotation exhibited that pathways including "cytokine-cytokine receptor interaction", "Th1 and Th2 cell differentiation", "cell adhesion molecules", and "antigen processing and presentation" were significantly enriched (Figure 4B and Table S5). In addition, GSEA algorithm and gene sets of cancer hallmarks were utilized to further explore the role of DLL3 in tumor progression. As displayed in Figure 4C and 4D, hallmarks and signaling pathways like "NOTCH signaling", "IL2-STAT5 signaling", "KRAS signaling", "TNFα signaling via NF-κB", "interferon-γ response", "inflammatory response", and "epithelial-mesenchymal transition" were significantly enriched in the low DLL3 expression group and there were no obvious hallmarks found in the high DLL3 expression group (Table S5). Therefore, DLL3 may suppress tumor development and metastasis by regulating immune responses and inhibiting various signaling pathways.

External and experimental validation of the prognostic value of DLL3 in UM and CM

To further validate the prognostic value of DLL3 in UM, we employed an external cohort consisting of 57 UM patients from GSE44295. The expression level of DLL3 in the non-metastatic UM samples was distinctly higher than that in the metastatic ones (Figure 5A). Kaplan-Meier survival curve demonstrated that UM patients with high DLL3 expression level exhibited longer metastasis-free survival than patients with low DLL3 expression level, highlighting the protective role of DLL3 in UM (Figure 5D). Considering the lack of UM cohorts with integrated data of gene expression and corresponding clinical information, we employed two external datasets containing a number of CM samples to test if DLL3 still worked well. As expected, the expression level of DLL3 in CM samples was significantly higher than that in the healthy conjunctiva tissues in both datasets (Figures 5B, C). In addition, DLL3 performed a promising power to distinguish CM samples from normal...
conjunctiva tissues in GSE143952 and GSE148387 with the AUC values of 0.99 and 0.792, respectively (Figures 5E, F).

Experimental validation of the role of DLL3 using biospecimens

Considering that the results above were based on public databases, we performed immunofluorescence using biospecimens to further verify the role of DLL3 in ocular melanoma. Of note, the expression of DLL3 was upregulated in ocular melanoma tissues compared to normal melanocyte tissues (p < 0.05, Figure 6A). Besides, patients with a high expression level of DLL3 showed favorable clinical outcomes (Figures 6B, C). High DLL3 expression prolonged the OS of patients with ocular melanoma (Figure 6D). Similarly, Kaplan-Meier curve indicated that patients with lower DLL3 expression are more likely to present with metastasis than patients with higher expression of this gene (Figure 6E). Patients with higher DLL3 expression have worse OS. Consistently, we also observed increased DLL3 expression in ocular melanoma cell lines (Figures 7A, B). Taken together, DLL3 may serve as a diagnostic and prognostic biomarker in ocular melanoma.

Discussion

Ocular melanoma, composed of UM and CM, is highly malignant with a poor prognosis. Ocular melanoma accounts for 4%-6% of melanomas with an increasing incidence. Almost 50% of ocular melanoma patients will develop metastasis within 10 years of treatments (32, 33). The clinical evaluation of ocular melanoma is fundamentally based on ophthalmoscopy, biomicroscopy, ultrasonography and radiography. MRI plays a significant role in disease evaluation (34). However, imaging examinations are hard to detect ocular melanoma at an early stage, as well as metastasis. Currently, the main treatment strategies for ocular melanoma include resection, adjuvant
chemoradiation and eye enucleation (35, 36). Nonetheless, most patients survive less than 12 months after metastatic diagnosis, as there is no effective treatment for metastatic ocular melanoma. Therefore, it is of great significance to explore the potential metastatic-related markers and potential therapeutic targets for preventing early-stage metastasis and improving the prognosis (37). It has been demonstrated that the genetic high-risk features, such as chromosome 8q gain and loss of $BAP1$, are frequent in patients with metastatic disease (38). Recently, high levels of nestin expression have been shown to correlate with metastatic progression and reduced survival rate in UM patients (39). Furthermore, Histopathologic identification achieved with immunohistochemistry using CD31 and D2–40 antibodies provides histopathologic evidence of extravascular spread of a primary CM (40). Caltabiano R. et al. evaluated the expression of $ADAM10$, $RKIP$ and $pRKIP$ and showed them as negative prognostic markers in UM (41, 42). In addition, Broggi G et al. identified ABCB5 as a prognostic factor in UM and observed that higher ABCB5 immunohistochemical levels were associated with a higher risk of metastasis (43). Lally SE et al. evaluated genetic mutations and molecular genetic pathways in CM and reported that loss of $ATRX$ and $ALT$ may be early events in CM. They also confirmed that $NRAS$ mutation implied an increased risk for metastasis and death in CM (44). Though mutations are frequently present in CM, little is known about prognostic genetic biomarkers due to the low incidence of this disease.

In this study, we found that $DLL3$ was a dysregulated methylation-driven gene that correlated with UM metastasis. Based on the positive correlation between the methylation and expression of $DLL3$, we inferred that $DLL3$ was highly expressed in the UM samples, which was further validated by biospecimens and cell lines. We investigated the role of $DLL3$ in the prognosis of patients with UM, finding that $DLL3$ could serve as a protective factor. The relationships between $DLL3$ and clinical characteristics indicated that UM patients with high $DLL3$ expression tended to achieve favorable clinical outcomes, including earlier pathological stage, prolonged overall survival, and a lower possibility to get disease recurred or progressed. In addition, $DLL3$ exhibited a promising power to distinguish CM from healthy conjunctiva. Therefore, the methylation-driven gene $DLL3$ may act as a diagnostic and prognostic biomarker in ocular melanoma.

The Notch signaling pathway is a highly conserved signaling pathway involved in a variety of development processes. $DLL3$ is an inhibitory Notch pathway ligand, which mediates cell-fate decisions and is tumor-suppressive or oncogenic depending on the cellular context (45). In small cell lung cancer (SCLC), $DLL3$ is highly expressed in more than 80% of patients and is highly expressed in both the cell membrane and cytoplasm of the tumor. Clinical studies have shown that the high expression of $DLL3$ in SCLC is negatively correlated with patient survival (46). $DLL3$ is identified as a regulator factor of SCLC-cell...
proliferation, migration, and invasion and an oncogene related to modulating Snail expression (45). In prostate cancer, DLL3 is highly expressed in a subset of advanced metastatic samples and is not notably expressed in non-metastasis samples or benign tissues (47). An antibody-drug conjugate that targets DLL3 named Rovalpituzumab tesirine (SC16LD6.5) has complete and durable responses in DLL3-expressing prostate cancer (47). In other cancer types, gene silencing of DLL3 induces intrinsic apoptosis, resulting in significant growth inhibition. For example, overexpression of DLL3 induces cellular apoptosis in human hepatocellular carcinoma. DLL3 expression is silenced during hepatocarcinogenesis in association with HBV infection via an epigenetic mechanism (48). For melanoma, knockdown of DLL3 inhibits inflammatory stimulation-induced melanoma cell migration and invasion by blocking Twist1-mediated epithelial-mesenchymal transition (EMT) (49). Although there

FIGURE 6
Ocular melanoma biospecimens were used to validate the aberrant expression and prognostic value of DLL3. (A) Representative immunofluorescence staining of DLL3 in ocular melanoma and normal melanocyte (left). Quantified data for DLL3 staining showed that the expression level of DLL3 in ocular melanoma samples was significantly high than that in normal melanocytic tissues (right). (B) Representative immunofluorescence staining of DLL3 in ocular melanoma samples from patients with different living statuses (left). Quantified data for DLL3 staining showed that the expression level of DLL3 in alive patients was significantly higher than that in patients who died during the follow-up (right). (C) Representative immunofluorescence staining of DLL3 in ocular melanoma patients with or without the metastasis occurrence (left). Quantified data for DLL3 staining showed that the expression level of DLL3 was higher in non-metastatic samples than that in metastatic ones (right). (D, E) Kaplan–Meier curves showed that high DLL3 expression significantly prolonged the overall survival (D) and metastasis-free survival (E) of patients with ocular melanoma. Scale bar = 50 μm. *P < 0.05.
are no previous studies on DLL3 in uveal melanoma, DLL4 was confirmed to be associated with the metastatic risk in uveal melanoma and its expression is the most inversely correlated with patient survival, which activates the NOTCH signaling pathway in uveal melanoma cells and controls their growth and migration (50).

Functional annotation including GO terms and KEGG pathways enrichment analyses revealed that DLL3 mainly participated in the regulation of the immune process. Setting the hallmarks of cancer as the reference gene sets, GSEA demonstrated that hallmarks such as epithelial-mesenchymal transition and signaling pathways like NOTCH signaling, KRAS signaling, and TNF-α signaling via NF-κB were significantly enriched in the low DLL3 expression group. Epithelial-mesenchymal transition is a process of cell remodeling during which epithelial cancer cells acquire migratory abilities (51). KRAS is the most frequently mutated oncogene and KRAS signaling functions as a main driver of tumorigenesis and development in various human cancers (52). Increasing evidence indicated that KRAS signaling could modulate the tumor microenvironment and promote tumor-related immune response (53), which was also found to be enriched in the low DLL3 expression group. TNFα is a cytokine that mainly participates in inflammation and immune response, while in tumors, it’s reported that TNFα-NF-κB signaling plays a crucial role in promoting tumor cell migration and invasion (54). On the contrary, there were no hallmarks found in the high DLL3 expression group. Taken together, it’s not surprising that UM patients with higher expression of DLL3 were more likely to have good clinical outcomes.

There were also some limitations to our study. First, our study was mainly based on public retrospective datasets. Moreover, the sample size was limited and uneven sample sizes were between conjunctival melanoma and uveal melanoma. Conclusions need to be further verified by large sample studies. Besides, we used clinical data to verify the conclusions drawn from bioinformatics while the detailed molecular mechanism has not been elucidated. The relationship between DLL3 DNA methylation and DLL3 expression needs to be further validated by experiments.

In summary, this is the first study to identify that DLL3, a methylation-driven gene, may serve as a new potential diagnostic and prognostic biomarker in ocular melanoma. Our study may help improve the clinical outcomes of patients with UM or CM.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

This research was performed in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from all patients. The study was approved by the Ethics Committee of Shanghai JiaoTong University.

Author contributions

LY and GW designed the study, analyzed data, and wrote the manuscript. SG, JR and RC designed the study and provided
funding acquisition. LY, HS and SJ performed the experiments and analyzed the data. All authors read and approved the final submitted manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (No. U1932135 and No. 12275178), the Science and Technology Commission of Shanghai (20DY2270800 and 22Y31900700), the Shanghai Pujiang Program (21PJD036), the Research project of Shanghai Municipal Health Commission (20204Y0302).

Acknowledgments

The authors would like to thank the TCGA and GEO databases for the availability of the data.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.964902/full#supplementary-material

SUPPLEMENTARY FIGURE 1
The quality control analyzes of samples from GSE57362. (A) PCA plot to visualize the relationship between UM and uvea samples. (B) Heatmap to exhibit the correlation among samples from GSE57362. (C) Heatmap to show the representative differential methylation CpGs between UM samples and normal uvea tissues.

SUPPLEMENTARY TABLE 2
DEGs between metastatic UM samples and non-metastatic ones as well as DEGs between low and high DLL3 expression groups.

SUPPLEMENTARY TABLE 3
The correlation between the DEGs expression level and their DNA methylation level in UM. *P < 0.05, **P < 0.01.

SUPPLEMENTARY TABLE 4
The methylation level of CpGs in DLL3 was positively associated with UM.

SUPPLEMENTARY TABLE 5
The results of GO terms and KEGG pathways enrichment analyses as well as the results of GSEA of cancer hallmarks.

References

1. Smit KN, Jager MJ, de Klein A, Kliq E. Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res (2020) 75:100800. doi: 10.1016/j.preteyeres.2019.100800

2. Bagger M, Smidt-Nielsen I, Andersen MK, Jensen PK, Heegaard S, Andersen KK, et al. Long-term metastatic risk after biopsy of posterior uveal melanoma. Ophthalmology (2018) 125(12):1969–76. doi: 10.1016/j.ophtha.2018.03.047

3. Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Laby SE, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology (2011) 118(23):389–95.e1-2. doi: 10.1016/j.ophtha.2010.06.021

4. Shields CL, Shields JA, Gunduz K, CATER I, Mercado GV, Gross N, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol (2000) 118(11):1497–507. doi: 10.1001/archopht.118.11.1497

5. Moore AR, Ran L, Guan Y, Sher JJ, Hitchman TD, Zhang JQ, et al. GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma. Cell Rep (2018) 22(9):2455–68. doi: 10.1016/j.celrep.2018.01.081

6. Singh N, Singh R, Bowen RC, Abdel-Rahman MH, Singh AD. Uveal melanoma in BAP1 tumor predisposition syndrome. Estimation of risk. Am J Ophthalmol (2021) 224:172–7. doi: 10.1016/j.ajo.2020.12.005

7. Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers (2020) 6(1):24. doi: 10.1038/s41572-020-0158-0

8. Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dabvoy SR, et al. Molecular characteristics of conjunctival melanoma using whole-exome sequencing. JAMA Ophthalmol (2017) 135(12):1434–7. doi: 10.1001/jamaophthalmol.2017.4837

9. Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet (2018) 14(6):e1007362. doi: 10.1371/journal.pgen.1007362

10. Moore LD, Le T, Fan G. DNA Methylation and its basic function. Neuropsychopharmacology (2013) 38(1):23–38. doi: 10.1038/npp.2012.112

11. Hou P, Ji M, Ge C, Shen J, Li S, He N, et al. Detection of methylation of human p16(Ink4a) gene 5′-CpG islands by electrochemical method coupled with linker-PCR. Nucleic Acids Res (2003) 31(16):e92. doi: 10.1093/nar/gng092

12. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 26(4):577–90. doi: 10.1016/j.ccell.2014.07.028

13. Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, et al. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer (2019) 18(1):161. doi: 10.1186/s12943-019-1088-x

14. Li Y, Jia R, Ge S. Role of epigenetics in uveal melanoma. Int J Biol Sci (2017) 13(4):426–33. doi: 10.7150/ijbs.18331

15. Rocco J, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 264(1):42–55. doi: 10.1006/excr.2000.5149
van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, et al. Promoter hypermethylation: a common cause of reduced p16 (INK4a) expression in uveal melanoma. *Cancer Res* (2001) 61(13):5303–6.

16. Zerougouei D, Fernandes BF, González S, Novais GN, Schalper KA, Burnier MN Jr. p16INK4a expression in benign and malignant melanocytic conjunctival lesions. *Int J Surg Pathol* (2012) 20(3):240–5. doi: 10.1177/1066116011453697

17. Dubois F, Bergot E, Levillat G. Cancer and RASSFIA/RASSF1C, the two faces of Janus. *Trends Cancer* (2019) 5(11):662–5. doi: 10.1016/j.trecan.2019.10.001

18. Jursek P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. *J Pathol* (2022) 256(1):61–70. doi: 10.1002/path.5808

19. Maat W, Behoer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA. Epigenetic regulation identifies RASFE as a tumor-suppressor gene in uveal melanoma. *Invest Ophthalmol Vis Sci* (2008) 49(4):1291–8. doi: 10.1167/iovs.07-1135

20. Field MG, Durante MA, Decatur CI, Tatnall B, Oeltchlagner KM, Stone JF, et al. Epigenetic reprogramming and aberrant expression of PIRAM are associated with increased metastatic risk in class I and class II uveal melanomas. *Oncotarget* (2016) 7(37):59209–19. doi: 10.18632/oncotarget.10962

21. Gao J, Aksoy BA, Dresnogor U, Dresnogor G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* (2013) 6(269):11. doi: 10.1126/scisignal.2004088

22. Berdasco M, Ameur A, Horvathova Kajabova V, et al. Monosomy 3 in MR imaging-part I: MR imaging with pathologic correlation and technical development, functions and associated disorders. *Front Immunol* (2022) 13:847624. doi: 10.3389/fimmu.2022.847624

23. Berdasco M, Go´mez A, Báguas AM, Latos W, Zarémba K, Sieron A, et al. DNA Methylomes reveal biological networks involved in human eye development, functions and associated disorders. *Sci Rep* (2017) 7(1):11762. doi: 10.1038/s41598-017-12064-1

24. Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Mittelviefhaus H, Lapp T, et al. Mutational landscape and outcomes of conjunctival melanoma in 101 patients. *Ophthalmol* (2022) 129(6):679–93. doi: 10.1016/j.ophtha.2022.01.016

25. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, et al. ChAMP: a comprehensive and annotated regulatory annotation platform. *Bioinformatics* (2017) 33(24):3982–4. doi: 10.1093/bioinformatics/btx513

26. Love MI, Huber W, Anders S. Moderated estimation of fold change and effect size in RNA-Seq. *Genome Biol* (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8

27. Wu T, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (N Y)* (2021) 2(3):100141. doi: 10.1016/j.xinn.2021.100141

28. Righelato R, Libeiroz J, Ferreira P, Rossetto O, Almeida D, Ribeiro K, et al. Epithelial–mesenchymal transition gene expression in uveal melanoma patients; consequences for liquid biopsy. *Int J Mol Sci* (2020) 21(24):9651. doi: 10.3390/ijms21249651

29. Klutstein M, Nejman D, Green SJ, Kurz SC, Chiriboga L, Serrano J, et al. Cell surface markers and their potential as biomarkers for conjunctival melanoma. *Front Immunol* (2021) 12(1):66. doi: 10.3389/fimmu.2021.01001-w

30. Greiwank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, et al. Genetic and clinicopathologic analysis of metastatic uveal melanoma. *Med Pathol* (2014) 27(2):175–83. doi: 10.1038/modpathol.2013.138

31. Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. *J Pathol* (2022) 256(1):61–70. doi: 10.1002/path.5808

32. Frants RR, Doniz M, Horvathova Kajabova V, et al. ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. *Pathol Res Pract* (2016) 212(11):980–7. doi: 10.1016/j.prp.2016.08.003

33. Wu T, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (N Y)* (2021) 2(3):100141. doi: 10.1016/j.xinn.2021.100141

34. Horvathova Kajabova V, et al. Monosomy 3 in MR imaging-part II: treatment indications and complications. *Insights Imaging* (2021) 12(1):67. doi: 10.1186/s13244-021-01107-w

35. Soltysova A, Sedlackova T, Dvorakova D, Jasek K, Chokhachi Baradaran P, Horvathova Kajabova V, et al. Monosomy 3 influences epithelial-mesenchymal transition gene expression in uveal melanoma patients; consequences for liquid biopsy. *Int J Mol Sci* (2020) 21(24):9651. doi: 10.3390/ijms21249651

36. Poty PV, Travali M, Farina R, Palmucci S, Spatola C, Liardo RLE, et al. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-part I: treatment indications and complications. *Insights Imaging* (2021) 12(1):67. doi: 10.1186/s13244-021-01107-w

37. Bol KF, Donia M, Heegard S, Kidgaard JF, Svene IM. Genetic biomarkers in melanoma of the ocular region. What the medical oncologist should know. *Int J Mol Sci* (2020) 21(15):5231. doi: 10.3390/ijms21155231

38. Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? *Curr Opin Cell Biol* (2016) 43:5–13. doi: 10.1016/j.cceb.2016.06.002

39. Huang L, Guo Z, Wang F, Fu L. KRAS mutation from undruggable to druggable in melanoma. *Signal Transduct Target Ther* (2021) 6(1):386. doi: 10.1038/s41419-021-00780-4

40. Pandiani C, Strub T, Nottet N, Cheli Y, Gambi G, Pittaluga S, et al. Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanoma and identifies HES6 as a driver of the metastatic disease. *Cell Death Differ* (2021) 28(6):1990–2000. doi: 10.1038/s41418-020-00730-7

41. Lally SE, Milian T, Orolf M, Dalvin LA, Eberhart CG, Heffey CM, et al. Mutational landscape and outcomes of conjunctival melanoma in 101 patients. *Ophthalmol* (2022) 129(6):679–93. doi: 10.1016/j.ophtha.2022.01.016

42. Frants RR, Doniz M, Horvathova Kajabova V, et al. ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. *Pathol Res Pract* (2016) 212(11):980–7. doi: 10.1016/j.prp.2016.08.003